Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia

AIDS
S FosterJ Porter

Abstract

To assess the economic benefits and costs of providing isoniazid preventive therapy for tuberculosis (TB) in HIV-infected persons in Zambia. A spreadsheet model incorporating variables drawn from published studies and unpublished data. Data drawn from a number of different studies and published literature involving a range of subjects. Zambia. Using data primarily from Zambia we have modelled the costs and benefits of a TB preventive therapy programme using daily isoniazid for 6 months. The basecase scenario assumes recruitment at a voluntary testing and counselling site where HIV seroprevalence is 30%; persons with HIV have a 25% probability of developing active TB during their lifetime; two additional cases of TB would be prevented per person completing a course of preventive therapy; compliance would be 63%, and the efficacy of the isoniazid in preventing active TB of 60%. The costs under this scenario would exceed the benefits by a factor of 1.16 [benefit: cost ratio (BCR) of 0.86]. However, if preventing one case of TB prevented an additional five cases, the benefits would exceed the costs by a significant margin (BCR of 1.71). Other scenarios indicate that the targeted preventive therapy of persons with HIV whose occupati...Continue Reading

References

Jul 22, 1992·JAMA : the Journal of the American Medical Association·P A SelwynE E Schoenbaum
Sep 1, 1990·BMJ : British Medical Journal·A M ElliottK P McAdam
Jan 1, 1994·Transactions of the Royal Society of Tropical Medicine and Hygiene·P KellyG Sipatunyana
Jul 1, 1995·Transactions of the Royal Society of Tropical Medicine and Hygiene·P Godfrey-FaussettK McAdam
Jul 27, 1995·The New England Journal of Medicine·S E KlineS F Davies
Feb 12, 1994·Lancet·P Reeve
Nov 1, 1994·American Journal of Public Health·K K LeonhardtM Aiken
Jul 1, 1993·Transactions of the Royal Society of Tropical Medicine and Hygiene·S J Heymann

❮ Previous
Next ❯

Citations

Jun 24, 2004·Health Policy·Stefano BertozziBernhard Schwartländer
Dec 23, 1998·Transactions of the Royal Society of Tropical Medicine and Hygiene·D Wilkinson, C F Gilks
Oct 6, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J D PassalarisM J Glesby
Aug 28, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael P DubéUNKNOWN HIV Medical Association of the Infectious Disease Society of America
Aug 30, 2007·The Journal of Infectious Diseases·Gavin J ChurchyardRichard E Chaisson
Mar 3, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Krishna P ReddyDavid A J Moore
Aug 17, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David N BurnsSten H Vermund
Sep 28, 2010·Clinical & Developmental Immunology·Kogieleum NaidooQuarraisha Abdool Karim
Aug 15, 2014·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Emily P HyleKenneth A Freedberg
Jan 25, 2008·Cost Effectiveness and Resource Allocation : C/E·Fern Terris-PrestholtPeter Godfrey-Faussett
Sep 26, 2015·The European Respiratory Journal·Haileyesus GetahunMario Raviglione

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.